Spyre Therapeutics
SYRE
55 hedge funds and large institutions have $22.6M invested in Spyre Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.36% less ownership
Funds ownership: 3.28% → 2.92% (-0.36%)
11% less capital invested
Capital invested by funds: $25.4M → $22.6M (-$2.76M)
17% less funds holding
Funds holding: 66 → 55 (-11)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$169K |
| 2 |
Millennium Management
New York
|
+$145K |
| 3 |
Two Sigma Advisers
New York
|
+$88.1K |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$37.1K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$27.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
-$1.43M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$1.16M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$255K |
| 4 |
D.E. Shaw & Co
New York
|
-$241K |
| 5 |
Renaissance Technologies
New York
|
-$164K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $828 | -$1.83K | -148 | -70% |
|
|
52
Dimensional Fund Advisors
Austin,
Texas
| – | -$255K | -20,253 | Closed |
|
|
53
D.E. Shaw & Co
New York
| – | -$241K | -19,056 | Closed |
|
|
LPC
54
Lion Point Capital
New York
| – | -$1.43M | -12,000 | Closed |
|
|
E
55
Ergoteles
New York
| – | -$74K | -5,888 | Closed |
|
56
UBS Group
Zurich,
Switzerland
| – | -$39K | -3,072 | Closed |
|
57
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$33K | -2,608 | Closed |
|
|
BCM
58
Bridgeway Capital Management
Houston,
Texas
| – | -$25K | -1,946 | Closed |
|
|
VF
59
Virtu Financial
New York
| – | -$16K | -1,246 | Closed |
|
60
SG Americas Securities
New York
| – | -$9K | -713 | Closed |
|
|
SSA
61
Schonfeld Strategic Advisors
New York
| – | -$5K | -404 | Closed |
|
62
Citigroup
New York
| – | -$2.25K | -182 | -88% |
|
63
Legal & General Group
London,
United Kingdom
| – | -$2K | -131 | Closed |
|
64
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | -60 | Closed |
|
|
CUAMC
65
China Universal Asset Management Company
Shanghai,
China
| – | +$284 | +23 | New |
|
SYRE Hedge Fund Activity: Q3 2022 in Review
55 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2022, worth a combined $22.6M — down 11% from $25.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SYRE and 4 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $169K. The largest seller was Lion Point Capital, exiting entirely with an estimated $1.43M sold.
- 55 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2022, down from 66 in Q2 2022.
- Funds reported $22.6M of Spyre Therapeutics stock for Q3 2022, down 11% quarter-over-quarter.
- 4 funds opened new Spyre Therapeutics positions in Q3 2022 and 15 closed out, a net change of -11 holders.
- The largest Spyre Therapeutics buyer in Q3 2022 was Rock Springs Capital Management, an estimated $169K added.
- The largest Spyre Therapeutics seller in Q3 2022 was Lion Point Capital, an estimated $1.43M sold.
Based on aggregated 13F filings for Q3 2022.